Attovia Therapeutics, Inc.

ATTO Nasdaq SEC CIK 2058707
Follow Attovia Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0 −100% vs same quarter last year
Net income −$22.3M −61.6% vs same quarter last year
EPS, diluted −$0.76 +77.9% vs same quarter last year
Operating cash flow −$25.7M −69.3% vs same quarter last year
Revenue by quarter
$0
$360K
$450K
$0
Q2 25 Q3 25 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing